Precision medicine approach to treating neurological disorders
(NASDAQ: PRAX)
(NASDAQ: PRAX)
Investors 3
Mentions in press and media 19
| Date | Title | Description |
| 29.09.2025 | ReCode Therapeutics Raises Over $29M in Additional Financing | ReCode Therapeutics, a Menlo Park, CA-based clinical-stage genetic medicines company, raised over $29M in additional funding. Backers were undisclosed. It also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) an... |
| 31.05.2025 | Vima Therapeutics: $60 Million Series A Secured For Advancing Oral Therapy For People With Dystonia And Movement Disorders | Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing led by Atlas Venture, with participation from Access Industries and Canaan. Vima ... |
| 13.01.2025 | Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities | Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1... |
| 05.04.2024 | Praxis Precision Medicines to Participate in Upcoming April Conferences | BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders... |
| 05.03.2024 | Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results | - |
| 08.01.2024 | Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio | Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg cohort Enrollment for both uli... |
| 15.06.2023 | Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering | - |
| 07.02.2023 | Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results | /EIN News/ -- Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline results expected for each of three ... |
| 06.01.2022 | Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advance Precision Medicines for Autoimmune Diseases | Alumis, formerly Esker Therapeutics, a precision immunology company backed by Foresite Capital and incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the completi... |
| 16.08.2021 | Praxis Precision Medicines : Provides Corporate Update and Reports Second Quarter 2021 Financial Results (Form 8-K) | Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 toplin... |
Show more